There is paper on it being used in the ICU but in real everyday situations, will it? The Toray device is to used with the Spectral Endotoxin Activity Assay test that measures levels of endotoxin. Endotoxin is a precursor to cytokines. Cytosorb is a cytokine filter. There is room for both in the sepsis market, targeting a specific patient population.
One thing, the007doc stated that catheter can only be inserted by skilled professionals in two areas in the hospital -- intensive care and the renal wards. He also stated that he has "difficulty seeing the critical care capacity for treatment of mild to moderate sepsis given the need for a hamofiltration circuit-this cannot be done on a normal ward and the renal wards are full and tend not to take acute medical patients." DrDoctor7 pretty much stated something similar.
Dr Lowenstein, is the Spectral/Toray device intended to be used in the ICU or outside the ICU?
----------------
And for those interested, here is how CTSO describes how the Cytosorb and Betasorb is used:
Technology, Products and Applications
For approximately the past half-century, the field of blood purification has been focused on hemodialysis, a mature, well accepted medical technique primarily used to sustain the lives of patients with permanent or temporary loss of kidney function. It is widely understood by the medical community that dialysis has inherent limitations in that its ability to remove toxic substances from blood drops precipitously as the size of toxins increases. Our hemocompatible adsorbent technology is expected to address this shortcoming by removing toxins largely untouched by dialysis.
Our products, CytoSorbTM and BetaSorbTM , are known in the medical field as hemoperfusion devices. During hemoperfusion, blood is removed from the body via a catheter or other blood access device, perfused through a filter medium where toxic compounds are removed, and returned to the body.
We believe that our polymer adsorbent technology may remove middle molecular weight toxins, such as cytokines, circulating in the blood. We believe that our technology may have many applications in the treatment of common, chronic and acute healthcare complications including the treatment and/or prevention of sepsis; the treatment of chronic kidney failure; the treatment of liver failure; the prevention of post-operative complications of cardiopulmonary bypass surgery; and the prevention of damage to organs donated by brain-dead donors prior to organ harvest. These applications vary by cause and complexity as well as by severity but share a common characteristic i.e. high concentrations of toxins in the circulating blood.
Both the CytoSorbTM and BetaSorbTM devices consist of a cylinder containing adsorbent polymer beads, although the polymers used in the two devices are physically different. The cylinders in both devices incorporate industry standard connectors at either end of the device which connect directly to the extra-corporeal circuit (bloodlines) in series with a dialyser, in the case of the BetaSorbTM device, or as a stand alone device in the case of the CytoSorbTM device. Both devices will require no additional expensive equipment, and will require minimal training.
The extra-corporeal circuit consists of plastic blood tubing, our CytoSorbTM or BetaSorbTM cartridge, as applicable, containing adsorbent polymer beads, pressure monitoring gauges, and a blood pump to maintain blood flow. The patient's blood is accessed through a catheter inserted into his or her veins. The catheter is connected to the extra-corporeal circuit and the blood pump draws blood from the patient, pumps it through the cartridge and returns it back to the patient in a closed loop system.
Market Data 
Markets 
AI
